Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Short Interest Update

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) was the target of a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 8,500 shares, an increase of 214.8% from the November 30th total of 2,700 shares. Based on an average daily volume of 898,500 shares, the days-to-cover ratio is currently 0.0 days.

Provectus Biopharmaceuticals Stock Up 2.3 %

Provectus Biopharmaceuticals stock traded up $0.00 during trading hours on Thursday, hitting $0.12. The stock had a trading volume of 162,587 shares, compared to its average volume of 255,911. Provectus Biopharmaceuticals has a 1-year low of $0.04 and a 1-year high of $0.22. The stock’s fifty day moving average is $0.12 and its two-hundred day moving average is $0.11.

About Provectus Biopharmaceuticals

Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.